Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

[1]  J. Pannek,et al.  Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany , 2010, World Journal of Urology.

[2]  G. Kramer,et al.  Treatment of Neurogenic Detrusor Overactivity with Botulinum Toxin A: The First Seven Years , 2009, Urologia Internationalis.

[3]  V. Forin,et al.  Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. , 2009, Journal of pediatric urology.

[4]  N. Őzgirgin,et al.  Urinary dysfunction in multiple sclerosis , 2009, Journal of Clinical Neuroscience.

[5]  J. Pannek,et al.  EAU guidelines on neurogenic lower urinary tract dysfunction. , 2009, European urology.

[6]  B. Schurch,et al.  Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. , 2007, European urology.

[7]  B. Schurch,et al.  Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. , 2007, Archives of physical medicine and rehabilitation.

[8]  L. Brundin,et al.  Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity , 2007, Scandinavian journal of urology and nephrology.

[9]  T. Riise,et al.  Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis , 2007, Multiple sclerosis.

[10]  K R Abrams,et al.  Systematic review and evaluation of methods of assessing urinary incontinence. , 2006, Health technology assessment.

[11]  W. Kitisomprayoonkul,et al.  Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. , 2005, Archives of physical medicine and rehabilitation.

[12]  P. Dasgupta,et al.  A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. , 2005, The Journal of urology.

[13]  T. Kessler,et al.  Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? , 2005, Neurourology and urodynamics.

[14]  J. Cadoret,et al.  Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. , 2005, The Canadian journal of urology.

[15]  V. Bini,et al.  Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. , 2004, The Journal of urology.

[16]  Emmanuel Chartier-Kastler,et al.  European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. , 2004, European urology.

[17]  P. Navarra,et al.  New therapeutic options for refractory neurogenic detrusor overactivity. , 2004, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[18]  K. Andersson Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.

[19]  B. Schurch,et al.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. , 2000, The Journal of urology.

[20]  N. Resnick,et al.  Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. , 2000, The Journal of urology.

[21]  A. Jackson,et al.  Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. , 1999, Archives of physical medicine and rehabilitation.

[22]  R. Swingler,et al.  Urinary, faecal and sexual dysfunction in patients with multiple sclerosis , 1999, Journal of Neurology.

[23]  D L Patrick,et al.  Quality of life of persons with urinary incontinence: development of a new measure. , 1998, Urology.

[24]  F. Biering-Sørensen,et al.  Urinary incontinence in spinal cord injured individuals 10–45 years after injury , 2010, Spinal Cord.

[25]  M. Brin,et al.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. , 2005, The Journal of urology.

[26]  J. Donovan,et al.  ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence , 2004, Neurourology and urodynamics.

[27]  M. Fall,et al.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. , 2002, American journal of obstetrics and gynecology.

[28]  A. Rossier,et al.  The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures , 1999, Neurourology and urodynamics.

[29]  A. Victor,et al.  Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction , 1998, Neurourology and urodynamics.

[30]  J. Donovan,et al.  Outcome measures for research in treatment of adult males with symptoms of lower urinary tract dysfunction , 1998, Neurourology and urodynamics.